FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, endocrinology, and can be used to treat diabetes and/or obesity. Method comprises administering a therapeutically effective amount of a composition in a solid oral dosage form containing glucagon-like peptide-1 (GLP-1 peptide) having a plasma half-life in the human body of at least 60 hours, and an enhancer that is a salt of a medium chain fatty acid. Composition is administered such that the ratio between the half-life of said peptide from the plasma in the human body expressed in days and the dosage interval of said composition expressed in days is more than 2:1.
EFFECT: use of the invention makes it possible to increase the effectiveness of treatment and to reduce the number of side effects by decreasing the variability of GLP-1 peptide concentration in plasma between doses.
15 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| DOSING SCHEMES FOR ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE 2 (GLP-2) ANALOGUES | 2018 |
|
RU2785662C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE | 2005 |
|
RU2385879C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
